Take the next step to see if you may qualify for this RMS study.
But don’t delay — space is limited!
An Eli Lilly clinical research study for adults with Relapsing Multiple Sclerosis (RMS) is enrolling.
Take the next step to see if you may qualify for this RMS study.
But don’t delay — space is limited!
This RMS study is enrolling adults ages 18 to 55 who have a Relapsing form of Multiple Sclerosis (including Relapsing-Remitting and Active Secondary Progressive MS).
Those who qualify may receive*:
• No-cost study-related care from local doctors
• No-cost investigational study medication
• Compensation for your time
No health insurance or referrals needed.
Take the next step to see if you may qualify for this RMS study. But don’t delay — space is limited!
Take the next step
to see if you may
qualify for this
RMS study.
But don’t delay —
space is limited!
Why Eli Lilly’s study on Relapsing Multiple Sclerosis is so important…
Multiple Sclerosis (MS) is an on-going autoimmune disease of the central nervous system (CNS). By “autoimmune,” we mean that the body’s own immune system attacks certain tissue. In MS, the tissue covering nerve fibers in the brain, spinal cord, and eyes called the “myelin sheath” are affected. Much like the plastic around an electrical cord, the sheath protects these nerves so they can send electrical signals that control movement as well as other functions. However, when the sheath is damaged, scar tissue forms and disrupts communication between the brain and the body.
As a result, MS symptoms include things like speech problems, poor balance, gait changes, muscle numbness or weakness, and blurry vision, for example.
About 4 out of 5 of those with MS have relapsing-remitting disease, meaning there will be periods when symptoms will flare, followed by a period of remission when symptoms improve or go away.
As there is still no cure for MS, more treatment options are needed.
This Eli Lilly RMS study is now assessing an investigational MS medication that works in a more targeted way than many existing treatments, which may result in fewer side effects.
Researchers want to assess it at different doses to see if it can help reduce both the number of new brain lesions and symptom relapses—but we need volunteers. Rest assured that even if you choose to enroll, you may still leave the study at any time, for any reason. Act now to see if you may qualify.
How does the online screener work?
Answer some questions about your health
Tell us a little bit about yourself
Connect to an available study in your area
Just takes a
few minutes
AcurianHealth helps connect people with research studies that offer treatment under development. Since 1998, AcurianHealth has referred 1 million study candidates to 800 studies in 70 countries.
©2023 Acurian, Inc. All rights reserved.
*In a research study, the participants may receive investigational study product or may receive an inactive substance, or placebo, depending on the study design. Participants receive study-related care from a doctor/
research team for the duration of the study. For studies that offer compensation, reasonable payments will be made for participation. The length of the study may vary.